Inventor · disambiguated record
David A. Moreno
Also filed as: MORENO DAVID · MORENO DAVID A · MORENO DAVID AUSTIN
39 granted patents·9 pending applications·175 citations·filing 2009–2025
97Inventor score
Top patents by PatentIndex Score
48 records- 0198US10112942B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Oct 30, 2018·29 cites·30 claims
- 0297US10953005B1Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted Mar 23, 2021·4 cites·16 claims
- 0397US10137124B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 27, 2018·12 cites·29 claims
- 0496US10208024B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2016·Granted Feb 19, 2019·32 cites·27 claims
- 0596US10172851B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·8 cites·29 claims
- 0694US11414404B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2020·Granted Aug 16, 2022·5 cites·14 claims
- 0794US10555944B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Feb 11, 2020·10 cites·12 claims
- 0893US8697715B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2013·Granted Apr 15, 2014·21 cites·25 claims
- 0991US10172845B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Jan 8, 2019·4 cites·29 claims
- 1089US11802127B23,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitorsPFIZER·Filed 2022·Granted Oct 31, 2023·1 cites·53 claims
- 1189US10144734B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 4, 2018·6 cites·30 claims
- 1288US10441581B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Oct 15, 2019·2 cites·29 claims
- 1387US11998545B2Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2023·Granted Jun 4, 2024·0 cites·14 claims
- 1485US9763942B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Sep 19, 2017·5 cites·18 claims
- 1585US9259470B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2014·Granted Feb 16, 2016·6 cites·45 claims
- 1684US10745419B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2018·Granted Aug 18, 2020·2 cites·19 claims
- 1783US9708290B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jul 18, 2017·3 cites·12 claims
- 1882US10881652B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Jan 5, 2021·2 cites·14 claims
- 1982US10154995B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 18, 2018·3 cites·18 claims
- 2081US11098064B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrileLOXO ONCOLOGY INC·Filed 2020·Granted Aug 24, 2021·1 cites·9 claims
- 2181US9670208B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2016·Granted Jun 6, 2017·4 cites·19 claims
- 2280US9187462B2Substituted quinazolines as serine/threonine kinase inhibitorsBLAKE JAMES F·Filed 2012·Granted Nov 17, 2015·6 cites·21 claims
- 2380US2023090520A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2477US8394795B2Pyrazole [3, 4-B] pyridine Raf inhibitorsAHRENDT KATERI A·Filed 2009·Granted Mar 12, 2013·5 cites·45 claims
- 2576US11691973B23,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitorsPFIZER·Filed 2022·Granted Jul 4, 2023·0 cites·11 claims
- 2676US8338452B2Raf inhibitor compounds and methods of use thereofAHRENDT KATERI A·Filed 2009·Granted Dec 25, 2012·4 cites·49 claims
- 2776US2021186959A1Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Application pending·0 cites
- 2875US2024002384A13,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitorsPFIZER·Filed 2023·Application pending·0 cites
- 2972US11648243B2Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2020·Granted May 16, 2023·0 cites·20 claims
- 3071US11634409B2Compounds for the treatment of BRAF-associated diseases and disordersARRAY BIOPHARMA INC·Filed 2022·Granted Apr 25, 2023·0 cites·42 claims
- 3171US2025263411A13,4-dihydro-2,7-naphthyridine-1,6(2h,7h)-diones as mek inhibitorsPFIZER·Filed 2025·Application pending·0 cites
- 3269US11851434B2Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2021·Granted Dec 26, 2023·0 cites·16 claims
- 3369US11807651B2Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrileLOXO ONCOLOGY INC·Filed 2021·Granted Nov 7, 2023·0 cites·11 claims
- 3468US12303509B2Compounds for the treatment of BRAF-associated diseases and disordersPFIZER·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 3565US10766881B22-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Sep 8, 2020·0 cites·21 claims
- 3662US2025241915A1Compounds for the treatment of braf-associated diseases and disordersPFIZER·Filed 2025·Application pending·0 cites
- 3758US10519126B2Serine/threonine kinase inhibitorsARRAY BIOPHARMA INC·Filed 2017·Granted Dec 31, 2019·0 cites·4 claims
- 3853US12351571B2Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Jul 8, 2025·0 cites·12 claims
- 3951US11168090B2Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2018·Granted Nov 9, 2021·0 cites·12 claims
- 4050US11603374B2Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Mar 14, 2023·0 cites·12 claims
- 4149US11472802B2Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Oct 18, 2022·0 cites·11 claims
- 4248US12180207B2Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinasesARRAY BIOPHARMA INC·Filed 2019·Granted Dec 31, 2024·0 cites·14 claims
- 4347US11964988B2Fused heterocyclic compounds as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Apr 23, 2024·0 cites·18 claims
- 4447US11524963B2Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitorsARRAY BIOPHARMA INC·Filed 2019·Granted Dec 13, 2022·0 cites·18 claims
- 4541US2014228349A15,7-substituted-imidazo[1,2-c]pyrimidinesARRAY BIOPHARMA INC·Filed 2012·Application pending·0 cites
- 4638US2013018033A1Raf inhibitor compounds and methods of use thereofARRAY BIOPHARMA INC·Filed 2010·Application pending·0 cites
- 4735US2012157452A11h-pyrazolo[3,4-b] pyridine compounds for inhibiting raf kinaseGRADL STEFAN·Filed 2010·Application pending·0 cites
- 4834US2012157439A1Raf inhibitor compounds and methods of use thereofALIAGAS IGNACIO·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David A. Moreno files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →